Psychedelic Stocks Index Popped 8% Last Week, Led By Incannex
Image Source: Pixabay
The 5 constituents in the munKNEE Psychedelic Compound-Based Drug Stocks Index jumped 8.1%, on average, last week. The best week was had by Incannex Healthcare's 47.2% increase based on the successful completion of a pre-IND (Investigational New Drug) meeting with the U.S. Food and Drug Administration (FDA) regarding the development of CannQuit-N for tobacco smoking cessation and control of relapse driving the Index up 23.3% YTD.
Below is how each constituent stock performed last week, in descending order, and YTD, plus any recent news, commentary, and/or analysis on each company:
- Incannex Healthcare (IXHL): up 47.2% last week; Unchanged YTD
- is researching and developing therapies and products with the world's largest portfolio of medicinal cannabinoid and psychedelic pharmaceutical products.
- Latest News, Commentary and/or Analysis:
- Mind Medicine (MNMD): up 11.6% last week; up 34.4% YTD
- Atai Life Sciences (ATAI): up 3.0% last week; up 30.5% YTD
- Compass Pathways (CMPS): up 1.8% last week; up 20.1% YTD
- is focused on the use of psilocybin (magic mushrooms) in their research. Go here for much more extensive information on Psilocybin.
- Latest News, Commentary and/or Analysis:
- GH Research (GHRS): down 0.6% last week; up 37.9% YTD
- is primarily focused on the use of mebufotenin, the new International non-proprietary name for 5-MeO-DMT, which stands for 5-MethOxy-N,N-DiMeThyltryptamine.
- Latest News, Commentary and/or Analysis:
Summary
The munKNEE Psychedelic Drug Stocks Index went up 8.1% last week and is now up 23.3% YTD.
More By This Author:
As Expected, Cannabis MSOs Continue To Decline
3 Poor Quarterly Financials Sink Cannabis LP Index
Get Ready: AI-Enabled Personal Computer Category About To Explode
Disclosure: None
This article has been composed with the exclusive application of the human intelligence (HI) of the author. No artificial intelligence (AI) technology has been deployed. ...
more